Komori
Takara Bio (4974) · InitiativeFirst stated

Development of MazF Gene Therapy

First written in FY2016. . Latest entry: FY2016.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Clinical development of MazF gene therapy for HIV infectionA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2016First statedAnnual report

    「Building on these results, since December 2012 we have been conducting a Phase I clinical trial of MazF gene therapy for HIV infection at the University of Pennsylvania and Drexel University in the United States.」

    A Phase I clinical trial is being conducted in the United States for HIV infection.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Takara Bio yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Development of MazF Gene Therapy | TAKARA BIO INC. (4974) | Komori